Medco, SureGene to Validate SULT4A1 Variants for Gauging Patient Response to Antipsychotic Drugs
August 25, 2010
Medco, SureGene to Validate SULT4A1 Variants for Gauging Patient Response to Antipsychotic Drugs
The alliance aims to validate whether polymorphisms identified by SureGene in the SULT4A1 gene can be used to stratify best responders to the four most widely prescribed atypical antipsychotics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- SureGene Receives IRS Funds, SBIR Matching Grant to Advance PGx of Antipsychotic Drugs
November 17, 2010 / Pharmacogenomics Reporter - Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs
May 9, 2012 / Pharmacogenomics Reporter - Medco to Evaluate Clinical Utility of AssureRx's PGx Test in Guiding Psychiatric Treatment
May 18, 2011 / Pharmacogenomics Reporter - People in the News: Felix Frueh, Stephen Quake, Jack Davis
October 3, 2012 / Pharmacogenomics Reporter - Knowledge of KIF6 Mutation Status Increases Patients' Statin Adherence, Medco Study Finds
March 28, 2012 / Pharmacogenomics Reporter